
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a promising biopharmaceutical company with a strong pipeline of drug candidates in various stages of development. Their recently started Phase 3 study for brepocitinib has the potential to be successful, given the positive results seen in their Phase 2 study. The company's other drug candidates, such as IMVT-1402, also show promising potential for various rare diseases. While potential risks include regulatory and commercial challenges, Roivant's innovative approach and potential partnerships could help mitigate these risks.
Bears say
Roivant Sciences is experiencing a negative outlook due to declining revenues, increasing losses, and substantial growth in R&D and SG&A expenses. This trend is likely to continue due to the higher program-specific spending and personnel-related expenses related to their drug candidates, resulting in a downward trend in their financial performance. Furthermore, with $3.9B in cash reserves, it is uncertain if Roivant Sciences will be able to achieve profitability in the near future.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares